Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK Plans Benlysta Expansion In Lupus Nephritis Based On Successful Phase III

Executive Summary

Benlysta was an early pioneer in systemic lupus erythematosus, but GSK now plans to expand the drug into the acute area, active lupus nephritis, with a filing in 2020.

You may also be interested in...



Keeping Track: Chiesi Breathes Easier With Bronchitol Approval; Submissions Aplenty From GSK, Pfizer, AZ, AbbVie

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker

10 Drug Launch Flops Of The Decade

The view from 2020: Scrip looks back over the last decade at the drug launches that defied expectations – for the worse.

Aurinia Closing In On Lupus Nephritis With Voclosporin

Canada’s Aurinia Pharmaceuticals expects to file a US NDA in the first half of next year on the use of its next-generation calcineurin inhibitor, voclosporin, in lupus nephritis, a condition with no approved therapies.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL026487

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel